Compare Otis Worldwide Corp (OTIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs BIO-TECHNE Corp — how do they compare? Otis Worldwide Corp trades at $65.83 (market cap $25.17B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Otis Worldwide Corp is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 65 Days and BIO-TECHNE Corp for 63 Days on average.
| OTIS | TECH | |
|---|---|---|
Market Cap | $25.17B | $11.36B |
Volume | 4,542,442 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $93.62 | $72.61 |
52-Week Low | $64.05 | $43.31 |
Typical Hold Time | 65 Days | 63 Days |
Enterprise Value | $33.20B | $11.39B |
Dividend Yield | 2.66% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.74, down 1.07% with a bearish technical signal and recent earnings misses. The stock trades near its 52-week low with mixed analyst sentiment (46.7% buy, 46.7% hold) despite a consensus price target of $87.00. Revenue growth remains stable at $14.43B (2025) with 10.17% net margins, though service margins face pressure from labor costs. Recent CEO succession news and China project wins provide strategic context amid weak equipment demand.
The outlook balances stable service revenue against margin pressures and China exposure. Upside exists if service margins recover and modernization backlog converts, but near-term headwinds and technical weakness suggest cautious positioning. Key risks include prolonged China weakness and execution on cost controls.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
